Brian Druker

Brian is the Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute and the co-founder of Blueprint Medicines. He revolutionized the treatment of cancer with the development of Gleevec (imatinib), a tyrosine kinase inhibitor that turned the once-fatal chronic myeloid leukemia into a manageable condition.

Brian currently serves on the board of directors at Amgen and Vincerx Pharma. He also has serves on the scientific advisory boards of Aptose Biosciences and Grail. He previously founded MolecularMD, which was acquired by ICON. Additionally, Brian is Associate Dean of Oncology at the OHSU School of Medicine and has been on the OHSU faculty since 1993.

Brian received an M.D. and a B.S. in Chemistry from the University of California, San Diego. He completed his internship and residency in internal medicine at Barnes Hospital, Washington University School of Medicine in St. Louis, and oncology training at Dana-Farber Cancer Institute.